CANAQUEST MEDICAL CORP CANQF, a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
Highlights derived from the study are as follows:
-
The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
-
These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).
-
CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.
Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.